Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 20/20 | 0.86 |
| ▸ | PPARA | Q07869 | 12/20 | 0.86 |
| ▸ | PPARG | P37231 | 5/20 | 0.86 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517514 | 0.95 | PPARD (0.88) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| Gw501516 SCHEMBL68714 | 0.93 | PPARD (1.00) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| Gw501516 SCHEMBL29356729 | 0.93 | PPARD (1.00) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL5519969 | 0.92 | PPARD (0.98) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL6235384 | 0.90 | PPARD (0.71) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL5520264 | 0.90 | PPARD (0.84) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL12989252 | 0.88 | PPARD (0.88) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL11950416 | 0.88 | PPARD (0.81) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL13078717 | 0.87 | PPARD (0.87) | PPARDPPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL13078718 | 0.87 | PPARD (0.87) | PPARDPPARAPPARGMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189895-B1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2005-06-08 | — | — | EP | claimed |
| US-6710063-B1 | Activators of PPAR delta | SMITHKLINE BEECHAM CORPORATION | 2004-03-23 | — | — | US | claimed |
| US-10426757-B2 | Compositions and methods for promoting intestinal stem cell and/or non-stem progenitor cell function | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2019-10-01 | — | — | US | disclosed |
| WO-2015184375-A2 | COMPOSITIONS AND METHODS FOR PROMOTING INTESTINAL STEM CELL AND/OR NON-STEM PROGENITOR CELL FUNCTION | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-12-03 | — | — | WO | disclosed |
| EP-1189895-B8 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1189895-B1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6723740-B2 | ADMINISTERING THERAPEUTIC AMOUNT OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST TO LOWER TRIGLYCERIDES | SMITHKLINE BEECHAM CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-6710063-B1 | Activators of PPAR delta | SMITHKLINE BEECHAM CORPORATION | 2004-03-23 | — | — | US | disclosed |
| US-20030203947-A1 | Administration of a therapeutic amount of a 1,3-thiazole-5-yl methylsulfanyl or 1,3-oxazole-5-yl methylsulfanyl derivative to a patient for lowering triglycerides | CHAO ESTHER YU-HSUAN (US) | 2003-10-30 | — | — | US | disclosed |
| EP-1189895-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXO GROUP LIMITED (GB) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001000603-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXO GROUP LIMITED (GB) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10426757-B2 | Compositions and methods for promoting intestinal stem cell and/or non-stem progenitor cell function | FABP2, ALPG, ALPI | PPARD 2842/4885PPARA 1257/4885PPARG 786/4885 |
| US-20030203947-A1 | Administration of a therapeutic amount of a 1,3-thiazole-5-yl methylsulfanyl or 1,3-oxazole-5-yl methylsulfanyl derivative to a patient for lowering triglycerides | PPARA, PPARD, PPARG | PPARD 2/4885PPARA 1/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.